NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS Abbott Laboratories ( ABT) target raised at UBS to $60. See company split as value creating. Maintain Buy rating. Agilent Technologies ( A) rated new Buy at UBS. $43 price target. Portfolio transformation is underappreciated. BB&T ( BBT) estimates, target increased at Citigroup Shares of BBT now seen reaching $24, according to Citigroup. Estimates also raised as NIM outlook reduced and appears reasonable. Neutral rating. City National ( CYN) numbers reduced at Jefferies. CYN estimates were cut through 2012. Company is seeing lower core earnings growth. Hold rating and new $41 price target. Cohen & Steers ( CVS) numbers cut at Goldman. CNS estimates were reduced through 2013. Company is realizing lower asset flows. Neutral rating and new $24 price target. CVS Caremark ( CVS) numbers raised at Citigroup. Shares of CVS now seen reaching $45. Estimates also increased on strong SSS. Maintain Buy rating. Dover ( DOV) estimates, target cut at Credit Suisse. Shares of DOV now seen reaching $65, according to Credit Suisse. Estimates also reduced, given slower electronic technology demand. Neutral rating. Eli Lilly ( LLY) numbers cut at Jefferies. Shares of LLY now seen reaching $33. Estimates also reduced, given margin pressures. Hold rating. General Electric ( GE) downgraded to hold a TheStreet ratings. General Electric estimates, target cut at Citigroup. Shares of GE now seen reaching $19. Estimates also lowered as pricing and margin headwinds are lingering longer than expected. Home Depot ( HD) estimates, target increased at Citigroup. Shares of HD now seen reaching $44. Estimates also raised as supply chain / technology initiatives provide significant runway for OM expansion. Honeywell International ( HON)numbers increased at Citigroup Shares of HON now seen reaching $55, according to Citigroup. Estimates also increased on strong 3Q and positioning for 2012. Neutral rating. Idacorp ( IDA) downgraded at Wells from Outperform to Market Perform. Valuation call. Kansas City Southern ( KSU) numbers boosted at Credit Suisse Shares of KSU now seen reaching $70, according to Credit Suisse. Estimates also upped, given the company's new business opportunities. Outperform rating. Lowe's ( LOW) numbers adjusted at Citigroup. Shares of LOW now seen reaching $23. Estimates lowered on continued underperformance versus Home Depot. Neutral rating.
Noble Energy ( NBL) upgraded at BMO from Market Perform to Outperform. Valuation call, based on a $120 price target. Nuance Communication ( NUAN) estimates, target increased at UBS. Shares of NUAN now seen reaching $29. Estimates also raised on positive Q4 pre release and convert debt. Buy rating. Owens & Minor ( OMI) numbers cut at UBS. Shares of OMI now seen reaching $31. Estimates also lowered on UBS hospital survey. Neutral rating. PetSmart ( PETM) estimates, target raised at Oppenheimer. Shares of PETM now seen reaching $58. Estimates also increased, as the company continues to deliver solid sales growth. Outperform rating. Saks ( SKS) upgraded at Deutsche from Sell to Hold. $9 price target. Sales trends have stabilized. Schlumberger ( SLB) estimates, target cut at Credit Suisse. SLB estimates were reduced through 2013. Business recovery is proving to be more gradual. Outperform rating and new $99 price target. Schlumberger estimates, target lowered at UBS. Shares of SLB now seen reaching $95. Estimates also lowered on near term North American pressure pumping concerns. Buy rating. Suntrust Banks ( STI) numbers lowered at Jefferies. Shares of STI now seen reaching $25. Estimates also cut, as the company is seeing higher mortgage costs. Buy rating. Texas Instruments ( TXN) estimates lowered at UBS through 2012. Expect in line 3Q with modest downside to 4Q. Maintain $32 price target and Buy rating. Verizon ( VZ) estimates lowered at Citigroup. VZ estimates lowered through 2012. Solid 3Q normalized wireline margin on a slower revenue recovery. Yahoo! ( YHOO) is upgraded to buy at TheStreet Ratings. Xerox ( XRX) estimates, target reduced at BMO. Shares of XRX now seen reaching $9. Estimates also cut, given lower expected sales. Market Perform rating.